Andrew Wilkins > Dechert LLP > Boston, United States > Lawyer Profile

Dechert LLP
BOSTON, MA 02110-2605
United States

Work Department

Intellectual Property




Andrew T. Wilkins, Ph.D. is a partner in Dechert’s intellectual property group, focusing his practice on patent law relating to biotechnology. Dr. Wilkins has extensive experience representing biotech companies and investors in strategic international patent portfolio development and life cycle management, as well as non-infringement and invalidity analysis, post-grant proceedings and IP due diligence.

Dr. Wilkins has advised clients on matters relating to an array of biotech areas, including: therapeutic antibodies and antibody-like molecules for oncology, autoimmune, cardiovascular and infectious disease indications; immunotherapy, including CAR and recombinant TCR technologies, peptide-based vaccines and immune checkpoint antibodies; antibody and TCR discovery and engineering technologies; glycoengineering technologies, including antibody Fc glycoengineering technologies; viral delivery technologies, including lentiviral and AAV delivery technologies; gene therapy technologies, including gene replacement and gene editing technologies; biocompatible drug delivery vehicles, including controlled release nanoparticle liposome technologies; drug screening assays; RNAi technologies; and Bayh-Dole compliance in the acquisition or licensing of IP based upon NIH-funded research.

In addition to his practice, Dr. Wilkins has prolific academic and industrial research experience, his previous roles including: an instructor in medicine at Harvard Medical School/Beth Israel Deaconess Medical Center in Boston; a graduate research student with GlaxoSmithKline, UK; a postdoctoral research associate with MRC Laboratory of Molecular Biology, UK; and an undergraduate research student with Celltech PLC, UK. He has authored/co-authored numerous scientific articles in top peer-reviewed journals, such as Genes and DevelopmentCurrent BiologyBiochemical JournalGenome BiologyCell Motility and the CytoskeletonTrends in Genetics and Methods in Enzymology.


  • University of Glasgow, B.Sc., Biochemistry
  • University of London, Ph.D., Molecular Cell Biology
  • Suffolk University Law School, J.D.

Lawyer Rankings

United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)

Recommended for being ‘diligent, comprehensive, collaborative, nimble, and resourceful’, Dechert LLP‘s practice is widely recognized as a highly-competitive player in the life sciences sector, regularly acting for pharmaceutical and biotechnology companies in a wide variety of matters, including patent portfolio development for pre-public and discovery stage clients, the management of international patent portfolios, multi-million dollar transactions, and disputes brought before the USPTO. Boston’s Andrea Reid and Andrew Wilkins, who joined the firm in February 2021 from Lathrop GPM, share the helm of the practice. Chad E. Davis, also in Boston, is another name to note. Carl Morales left the firm in October 2021.